PathAI Acquired by Roche | Healthcare M&A Deal

Roche has acquired PathAI, a diagnostics imaging business in Massachusetts, for $1.05 billion. Roche acquisitions target PathAI’s digital pathology platform that uses AI to analyze patient tissue samples and support cancer diagnosis workflows. Based in Boston, PathAI provides AI-enabled diagnostic tools and companion diagnostic algorithm development that can accelerate precision oncology decisions. This strategic acquisition is a merger acquisition announced by Roche Diagnostics, with $750 million upfront and up to $300 million in milestone payments, and is expected to close in the second half of 2026 subject to antitrust and regulatory approvals. Roche plans to integrate PathAI’s digital pathology tools with its oncology diagnosis platforms to scale globally and support translational research and clinical trial use cases.